Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results

Area of Science:

• Ophthalmology
• Biochemistry
• Pharmacology

Background:

• Diabetic retinopathy (DR) is a primary cause of vision loss in working adults.
• Current DR treatments, including glycemic control, blood pressure management, and laser surgery, have limitations.
• Carbonic anhydrases (CAs) are enzymes involved in CO2 and bicarbonate metabolism.

Purpose of the Study:

• To review the potential of carbonic anhydrase inhibitors (CAIs) as a novel therapeutic strategy for diabetic retinopathy.
• To summarize preclinical and clinical evidence supporting CAIs in DR treatment.
• To explore the underlying mechanisms of CAIs in the context of DR.

Main Methods:

• Review of existing clinical studies on CAIs for DR.
• Analysis of animal model studies investigating CAI efficacy in DR.
• Examination of biochemical pathways related to CA function in ocular tissues.

Main Results:

• Emerging evidence suggests CA inhibitors demonstrate therapeutic potential in both animal models and human clinical trials for DR.
• CAIs may offer a new mechanism for managing DR beyond current treatment paradigms.
• Studies indicate specific CA isoenzymes are implicated in DR pathogenesis.

Conclusions:

• Carbonic anhydrase inhibitors represent a promising therapeutic avenue for diabetic retinopathy.
• Further research into CAI mechanisms and clinical application is warranted.
• Targeting carbonic anhydrases could offer a novel approach to preserving vision in diabetic patients.